12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adcetris brentuximab vedotin: Phase III started

Seattle Genetics and Takeda's Millennium Pharmaceuticals Inc. subsidiary began an open-label, U.S. Phase III trial to compare 1.2 mg/kg IV Adcetris given on days 1 and 15 of a 28-day cycle plus doxorubicin, vinblastine and dacarbazine vs. doxorubicin, vinblastine, dacarbazine plus bleomycin in about 1,040 patients with stage III/IV classical Hodgkin's lymphoma. The trial has a SPA from FDA and received scientific...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >